Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 4,600 shares at $17.45 ($80K) on 2024-02-05, disclosed to the SEC on 2024-02-07.
Scheduled sale ($80k) by CHIEF SCIENTIFIC OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |
| AVTE | SELL | 2023-06-07 | $37K | — | Filing → |